Abstract
The aim of the study was to summarize available literature regarding the interaction between vitamin K antagonists (VKAs) and trimethoprim-sulfamethoxazole (co-trimoxazole, TMP-SMX), and to provide recommendations for managing patient risk from this interaction. Data sources were English-language publications in the medical literature and Internet databases. Relevant publications that directly or indirectly addressed the VKA-TMP-SMX interaction were selected and reviewed. The mechanism of the VKA-TMP-SMX interaction, frequency of concurrent use, effect on international normalized ratio (INR), increased risk of bleeding, and strategies for risk reduction are summarized. The concurrent use of VKA and TMP/SMX rapidly and consistently raises INR and is associated with a two- to five-fold increase in bleeding. Concurrent use of VKA and TMP-SMX should be avoided when possible. When VKA and TMP-SMX are co-prescribed, VKA dose reduction is usually required. Patient education as well as early and frequent INR monitoring is recommended to reduce risk from this interaction.
References
1. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31: 326–43.10.1007/s11239-011-0561-1Search in Google Scholar PubMed
2. Vitry AL. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007;63:709–14.10.1111/j.1365-2125.2006.02809.xSearch in Google Scholar PubMed PubMed Central
3. Classen DC, Phansalkar S, Bates DW. Critical drug-drug interactions for use in electronic health records systems with computerized physician order entry: review of leading approaches. J Patient Saf 2011;7:61–5.10.1097/PTS.0b013e31821d6f6eSearch in Google Scholar PubMed
4. Aronson JK. Communicating information about drug interactions. Br J Clin Pharmacol 2007;63:637–9.10.1111/j.1365-2125.2007.02948.xSearch in Google Scholar
5. Pharmacist’s Letter. Drug interaction overload: problems and solutions for drug interaction alerts. Pharmacist’s Letter/Prescriber’s Letter 2012; course no. 216, self-study course #120216. Available at: http://prescribersletter.therapeuticresearch.com/ce/cecourse.aspx?pc=12-216. Accessed March 2013.Search in Google Scholar
6. Feldstein AC, Smith DH, Perrin N, Yang X, Simon SR, Krall M, et al. Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med 2006;166:1009–15.10.1001/archinte.166.9.1009Search in Google Scholar PubMed
7. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol 2011;154:311–24.10.1111/j.1365-2141.2011.08753.xSearch in Google Scholar PubMed
8. Thi L, Shaw D, Bird J. Warfarin potentiation: a review of the “FAB-4” significant drug interactions. Consult Pharm 2009;24:227–30.10.4140/TCP.n.2009.227Search in Google Scholar PubMed
9. Alexandra J-F, Pautus E, Gouin-Thibault I, Siguret V, Loriet M-A. Overanticoagulation with coumarin and cutaneous azole therapy. Ann Int Med 2008;148:633–5.10.7326/0003-4819-148-8-200804150-00025Search in Google Scholar PubMed
10. Horn JR, Hansten PD. Warfarin drug interactions: the role of genetics. Pharmacy Times June1, 2008. Available at: http://www.pharmacytimes.com/publications/issue/2008/2008-06/2008-06-8583. Accessed October 15, 2013.Search in Google Scholar
11. Holbrook A, Schulman, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulation therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Practice Guidelines. Chest 2012;141(2 Suppl):e152S–84S.10.1378/chest.11-2295Search in Google Scholar PubMed PubMed Central
12. Bienema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008;100:1052–7.10.1160/TH08-04-0116Search in Google Scholar
13. O’Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33–5.10.1056/NEJM198001033020106Search in Google Scholar
14. Hassall C, Feetam CL, Leach RH, Meynell MJ. Letter: potentiation of warfarin by co-trimoxazole. Lancet 1975;2:1155–6.10.1016/S0140-6736(75)91057-0Search in Google Scholar
15. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP 2C9, respectively. Drug Metab Dispos 2002;30:631–5.10.1124/dmd.30.6.631Search in Google Scholar
16. Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009;41:619–28.10.1080/07853890903186168Search in Google Scholar
17. Ahmed A, Stephens JC, Kaus CA, Fay WP. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levoflxacin. J Thromb Thrombolysis 2008;26:44–8.10.1007/s11239-007-0164-zSearch in Google Scholar
18. Glasheen JJ, Fugit RV, Prochazka AV. Brief report: the risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med 2005;20:653–6.10.1007/s11606-005-0113-5Search in Google Scholar
19. Schalekamp T, van Geest-Daalderop JH, Kramer MH, van Holten-Verzantvoort AT, de Boer A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur J Clin Pharmacol 2007;63:335–43.10.1007/s00228-007-0268-6Search in Google Scholar
20. Takahashi H, Wilkinson GR, Padrini R, Echizen H. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 2004;75: 376–80.10.1016/j.clpt.2004.01.007Search in Google Scholar
21. Hansen JM, Siersbaek-Nielsen K, Skovsted L, Kampmann JP, Lumholtz B. Letter: potentiation of warfarin by co-trimoxazole. Br Med J 1975;2:684.Search in Google Scholar
22. Hansten PD, Horn JR. Drug interactions analysis and management, 4th ed. St. Louis, MO: Wolters Kluwer Health, 2009.Search in Google Scholar
23. Horn JR, Hansten PD. Enhanced warfarin response and antibiotics. Pharmacy Times 2004;6:70.Search in Google Scholar
24. Renton KW. Hepatic drug metabolism and immunostimulation. Toxicology 2000;142:173–8.10.1016/S0300-483X(99)00142-0Search in Google Scholar
25. Tilstone WJ, Gray JM, Nimmo-Smith RH, Lawson DH. Interaction between warfarin and sulphamethoxazole. Postgrad Med J 1977;53:388–90.10.1136/pgmj.53.621.388Search in Google Scholar PubMed PubMed Central
26. Lane MA, Devine ST, McDonald JR. High-risk antimicrobial prescriptions among ambulatory patients on warfarin. J Clin Pharm Ther 2012;37:157–60.10.1111/j.1365-2710.2011.01270.xSearch in Google Scholar PubMed PubMed Central
27. Raebel MA, Witt DM, Carroll NM, Magid DJ. Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy. Pharmacotherapy 2005;25:1055–61.10.1592/phco.2005.25.8.1055Search in Google Scholar PubMed
28. Snaith A, Pugh L, Simpson CR, McLay JS. The potential for interaction between warfarin and coprescribed medication: a retrospective study in primary care. Am J Cardiovasc Drugs 2008;8:207–12.10.2165/00129784-200808030-00007Search in Google Scholar PubMed
29. Verhovsek M, Motlagh B, Crowther MA, Kennedy C, Dolovich L, Campbell G, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr 2008;8:13.10.1186/1471-2318-8-13Search in Google Scholar PubMed PubMed Central
30. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004;24:1668–74.10.1592/phco.24.17.1668.52338Search in Google Scholar PubMed
31. Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008;25:151–9.10.1007/s11239-007-0048-2Search in Google Scholar PubMed
32. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11–7.10.1056/NEJM199507063330103Search in Google Scholar PubMed
33. Kucher N, Connolly S, Bekcman JA, Cheng LH, Tsilimingras KV, Fanikos J, et al. International normalized ratio increase before warfarin-associated hemorrhage. Arch Intern Med 2004;164:2176–9.10.1001/archinte.164.19.2176Search in Google Scholar PubMed
34. Barnett DB, Hancock BW. Anticoagulant resistance: an unusual case. Br Med J 1975;1:608–9.10.1136/bmj.1.5958.608Search in Google Scholar PubMed PubMed Central
35. Greenlaw CW. Drug interaction between co-trimoxazole and warfarin. Am J Hosp Pharm 1979;36:1155.10.1093/ajhp/36.9.1155Search in Google Scholar
36. Kaufman JM, Fauver HE. Potentiation of warfarin by trimethoprim-sulfamethoxazole. Urology 1980;XVI:601–3.10.1016/0090-4295(80)90568-3Search in Google Scholar
37. O’Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med 1979:91:34–6.10.7326/0003-4819-91-1-34Search in Google Scholar PubMed
38. Serlin MJ. Antimicrobial drug interactions with oral anticoagulants. J Antimicrob Chemother 1979;5:628–30.10.1093/jac/5.6.628Search in Google Scholar PubMed
39. Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 2009;86:425–9.10.1038/clpt.2009.95Search in Google Scholar PubMed
40. Holbrook AH, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165: 1095–1106.10.1001/archinte.165.10.1095Search in Google Scholar PubMed
41. Campbell JE, Carter WH. Comments on the important drug interaction of warfarin and sulfamethoxazole. Arch Intern Med 2005;165:2540.Search in Google Scholar
42. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 2011;183:1851–8.10.1503/cmaj.111152Search in Google Scholar PubMed PubMed Central
43. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007;177:369–71.10.1503/cmaj.070946Search in Google Scholar PubMed PubMed Central
44. Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002;88:705–10.10.1055/s-0037-1613289Search in Google Scholar
45. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001;69:451–7.10.1067/mcp.2001.115723Search in Google Scholar PubMed
46. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013;185:E121–7.10.1503/cmaj.121218Search in Google Scholar PubMed PubMed Central
47. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011;13:723–46.10.1093/europace/eur126Search in Google Scholar PubMed
48. Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalization or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005;94:537–43.10.1160/TH05-03-0166Search in Google Scholar PubMed
49. Long AL, Bendz L, Horvath MM, Cozart H, Eckstrand J, Whitehurst J, et al. Characteristics of ambulatory anticoagulation adverse drug events: a descriptive study. Thromb J 2010;8:5.10.1186/1477-9560-8-5Search in Google Scholar PubMed PubMed Central
50. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008;84:581–8.10.1038/clpt.2008.150Search in Google Scholar PubMed PubMed Central
51. Penning-van Beest FJ, Koerselman J, Herings RM. Risk of bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost 2008;6:284–90.10.1111/j.1538-7836.2008.02844.xSearch in Google Scholar
52. Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents. Arch Intern Med 2010;170:617–21.10.1001/archinternmed.2010.37Search in Google Scholar PubMed
53. Vitry AL, Roughead EE, Ramsay EN, Preiss AK, Ryan P, Gilbert AL, et al. Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf 2011;20:1057–63.10.1002/pds.2219Search in Google Scholar PubMed
54. Baillargeon J, Holmes HM, Lin YL, Mukaila AR, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med 2012;125:183–9.10.1016/j.amjmed.2011.08.014Search in Google Scholar PubMed PubMed Central
55. Aspinwall SL, Zhao X, Handler SM, Stone RA, Kosmoski JC, Libby EA, et al. The quality of warfarin prescribing and monitoring in veterans affairs nursing homes. J Am Geriatr Soc 2010;58:1475–80.10.1111/j.1532-5415.2010.02967.xSearch in Google Scholar PubMed PubMed Central
56. Lalonde L, Martineau J, Blais N, Montigny M, Ginsberg J, Fournier M, et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J 2008;156:148–54.10.1016/j.ahj.2008.02.009Search in Google Scholar PubMed
57. Horn JR, Hansten PD. Prophylactic dose adjustments in management of drug interactions. Pharmacy Times 2011;11:46.Search in Google Scholar
58. Strom BL, Schinnar R, Aberra F, Bilker W, Hennessy S, Leonard CE. Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction. Arch Intern Med 2010;170:1578–83.10.1001/archinternmed.2010.324Search in Google Scholar PubMed
59. Saverno KR, Hines LE, Warholak TL, Grizzle AJ, Babits L, Clark C, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc 2011;18:32–7.10.1136/jamia.2010.007609Search in Google Scholar PubMed PubMed Central
60. Pennsylvania Patient Safety Reporting System (PA-PSRS). Anticoagulation management service: safer care, maximizing outcomes. Pa Patient Saf Advis 2008;5:81–4.Search in Google Scholar
61. Ryan F, Byrne S, O’Shea S. Managing oral anticoagulation therapy: improving clinical outcomes. A review. J Clin Pharm Ther 2008;33:581–90.10.1111/j.1365-2710.2008.00959.xSearch in Google Scholar PubMed
62. Mitchiner JC, Korzeniewski SJ, Betten D, Castle D, Halasyamani L, Burns SM, et al. Evaluation of the B-SAFE campaign to reduce clinically significant warfarin drug-interactions among fee-for-service medicare beneficiaries. Am J Med Qual 2012;27: 518–23.10.1177/1062860612438706Search in Google Scholar PubMed
63. Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, et al. Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology 2010;116:61–9.10.1159/000314936Search in Google Scholar PubMed
64. Wofford JL, Wells MD, Singh S. Best strategies for patient education about anticoagulation with warfarin: a systematic review. BMC Health Serv Res 2008;8:40.10.1186/1472-6963-8-40Search in Google Scholar PubMed PubMed Central
65. PL Detail-Document. Antimicrobial drug interactions and warfarin. Pharmacist’s Letter/Prescriber’s Letter. August 2012. Available at: http://prescribersletter.therapeuticresearch.com/cat5584-Cardiology-Warfarin--Drug-Interactions/Browse.aspx?s=PRL. Accessed November 1, 2013.Search in Google Scholar
66. Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013;158: 861–8.10.7326/0003-4819-158-12-201306180-00003Search in Google Scholar PubMed
67. Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interactions involving warfarin: practice tool and practical management tips. CPJ/RPC 2011;144:21–5.e9.10.3821/1913-701X-144.1.21Search in Google Scholar
68. Baglin T. Avoiding overanticoagulation: knowing your antibiotics. Thromb Haemost 2002;88:703–4.10.1055/s-0037-1613288Search in Google Scholar
69. Holt RK, Anderson EA, Cantrell MA, Shaw RF, Egge JA. Preemptive dose reduction of warfarin in patients initiating metronidazole. Drug Metabol Drug Interact 2010;25:35–9.10.1515/DMDI.2010.002Search in Google Scholar PubMed
70. Dowd MB, Vavra KA, Witt DM, Delate T, Martinez K. Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. J Thromb Thrombolysis 2011;31:472–7.10.1007/s11239-010-0535-8Search in Google Scholar PubMed
71. Dowd MB, Kippes KA, Witt DM, Delate T, Martinez K. A randomized controlled trial of empiric warfarin dose reduction with initiation of doxycycline therapy. Thromb Res 2012;130:152–6.10.1016/j.thromres.2011.12.017Search in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin Boston
